Analysts Expect Synergy Pharmaceuticals, Inc. (SGYP) to Post -$0.22 EPS
Equities research analysts expect Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) to post ($0.22) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Synergy Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.26) and the highest estimate coming in at ($0.16). Synergy Pharmaceuticals reported earnings per share of ($0.31) during the same quarter last year, which would suggest a positive year over year growth rate of 29%. The business is scheduled to announce its next earnings report on Wednesday, March 7th.
According to Zacks, analysts expect that Synergy Pharmaceuticals will report full year earnings of ($1.13) per share for the current year, with EPS estimates ranging from ($1.20) to ($1.02). For the next year, analysts anticipate that the company will report earnings of ($0.51) per share, with EPS estimates ranging from ($0.71) to ($0.13). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that follow Synergy Pharmaceuticals.
Synergy Pharmaceuticals (NASDAQ:SGYP) last released its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.06. The company had revenue of $5.01 million during the quarter, compared to analyst estimates of $4.53 million. During the same period in the prior year, the firm posted ($0.22) EPS.
A number of analysts recently issued reports on the company. HC Wainwright set a $8.00 target price on Synergy Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, October 18th. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $9.00 target price on shares of Synergy Pharmaceuticals in a research report on Tuesday, July 18th. CIBC lowered their target price on Synergy Pharmaceuticals from $9.00 to $6.00 and set an “outperform” rating on the stock in a research report on Friday, September 8th. Citigroup Inc. reaffirmed a “sell” rating and issued a $2.50 target price (down previously from $3.20) on shares of Synergy Pharmaceuticals in a research report on Wednesday, September 13th. Finally, Canaccord Genuity set a $13.00 target price on Synergy Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, July 31st. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $8.39.
Synergy Pharmaceuticals (SGYP) traded down $0.25 during trading hours on Friday, hitting $2.72. The company had a trading volume of 20,258,900 shares, compared to its average volume of 5,231,931. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.07 and a current ratio of 2.33. Synergy Pharmaceuticals has a twelve month low of $2.56 and a twelve month high of $7.15.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/11/12/analysts-expect-synergy-pharmaceuticals-inc-sgyp-to-post-0-22-eps.html.
Institutional investors have recently bought and sold shares of the stock. Alliancebernstein L.P. boosted its holdings in shares of Synergy Pharmaceuticals by 25.9% during the second quarter. Alliancebernstein L.P. now owns 339,330 shares of the biopharmaceutical company’s stock worth $1,510,000 after acquiring an additional 69,800 shares during the period. Sei Investments Co. boosted its holdings in shares of Synergy Pharmaceuticals by 18.2% during the second quarter. Sei Investments Co. now owns 367,779 shares of the biopharmaceutical company’s stock worth $1,637,000 after acquiring an additional 56,595 shares during the period. Swiss National Bank boosted its holdings in shares of Synergy Pharmaceuticals by 14.4% during the second quarter. Swiss National Bank now owns 371,650 shares of the biopharmaceutical company’s stock worth $1,654,000 after acquiring an additional 46,800 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Synergy Pharmaceuticals by 60.9% during the second quarter. JPMorgan Chase & Co. now owns 1,988,200 shares of the biopharmaceutical company’s stock worth $8,848,000 after acquiring an additional 752,475 shares during the period. Finally, State of Wisconsin Investment Board bought a new stake in shares of Synergy Pharmaceuticals during the second quarter worth approximately $730,000. Institutional investors and hedge funds own 71.63% of the company’s stock.
Synergy Pharmaceuticals Company Profile
Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Synergy Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.